Medicines Co
MDCO
MDCO was delisted on the 3rd of January, 2020.
172 hedge funds and large institutions have $2.1B invested in Medicines Co in 2015 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 79 increasing their positions, 54 reducing their positions, and 33 closing their positions.
46% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 54
21% more call options, than puts
Call options by funds: $32.4M | Put options by funds: $26.7M
2% more capital invested
Capital invested by funds: $2.05B → $2.1B (+$48.4M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
7% less funds holding
Funds holding: 184 → 172 (-12)
36% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$36.3M |
| 2 |
CM
Corvex Management
New York
|
+$29.7M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$19.7M |
| 4 |
UBS AM
Chicago,
Illinois
|
+$17.3M |
| 5 |
BM
Bridger Management
New York
|
+$15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
-$52.3M |
| 2 |
Millennium Management
New York
|
-$31.3M |
| 3 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$29.5M |
| 4 |
Morgan Stanley
New York
|
-$25.9M |
| 5 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$18.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
201
Two Sigma Advisers
New York
| – | -$238K | -8,501 | Closed |
|
|
SCM
202
Stevens Capital Management
Radnor,
Pennsylvania
| – | -$210K | -7,504 | Closed |
|
|
SEC
203
Seven Eight Capital
New York
| – | -$132K | -4,700 | Closed |
|
|
PCM
204
Prelude Capital Management
New York
| – | -$81K | -2,900 | Closed |
|
205
Creative Planning
Overland Park,
Kansas
| – | -$56K | -2,000 | Closed |
|
|
RFC
206
Russell Frank Company
Seattle,
Washington
| – | -$50K | -1,787 | Closed |
|
MDCO Hedge Fund Activity: Q2 2015 in Review
172 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Medicines Co (MDCO) for Q2 2015, worth a combined $2.1B — up 2.4% from $2.05B a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of MDCO and 21 opened new positions — a net loss of 12 holders — while 54 trimmed existing stakes and 79 added.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $36.3M. The largest seller was Royce & Associates, cutting an estimated $52.3M.
- 172 institutional investors held Medicines Co (MDCO) as of Q2 2015, down from 184 in Q1 2015.
- Funds reported $2.1B of Medicines Co stock for Q2 2015, up 2.4% quarter-over-quarter.
- 21 funds opened new Medicines Co positions in Q2 2015 and 33 closed out, a net change of -12 holders.
- The largest Medicines Co buyer in Q2 2015 was PFM Health Sciences, an estimated $36.3M added.
- The largest Medicines Co seller in Q2 2015 was Royce & Associates, an estimated $52.3M sold.
Based on aggregated 13F filings for Q2 2015.